Literature DB >> 19568269

HPGD mutations cause cranioosteoarthropathy but not autosomal dominant digital clubbing.

Wenke Seifert1, Julia Beninde, Katrin Hoffmann, Tom H Lindner, Christian Bassir, Fuat Aksu, Christoph Hübner, Nienke E Verbeek, Stefan Mundlos, Denise Horn.   

Abstract

Cranio-osteoarthropathy, clinically classified as a variant of primary hypertrophic osteoarthropathy, is a very rare autosomal-recessive condition characterized by delayed closure of the cranial sutures and fontanels, digital clubbing, arthropathy, and periostosis. Recently, mutations in the gene HPGD, which encodes the NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase, were reported in four families affected with primary hypertrophic osteoarthropathy and one family with autosomal-recessive isolated nail clubbing. We report the clinical and molecular findings in four patients from two families affected with cranio-osteoarthropathy and one family with isolated, autosomal dominant digital clubbing. Genome-wide homozygosity mapping identified a locus for cranio-osteoarthropathy harboring the HPGD gene in one affected family. We detected two novel homozygous mutations in HPGD in these families: a missense mutation affecting the NAD(+) binding motif and a frameshift mutation. The clinical presentation in our patients was variable. Digital clubbing and hyperhidrosis were present in all cases. Delayed closure of the cranial sutures and fontanels, periostosis, and arthropathy were not consistent clinical features. No HPGD mutation was detected in a familial case of autosomal dominant isolated digital clubbing. The failure to identify any mutation in a family with an autosomal dominant type of isolated digital clubbing suggests that HPGD is not the major gene for this condition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19568269      PMCID: PMC2987025          DOI: 10.1038/ejhg.2009.104

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  14 in total

1.  Metabolism of PGE2 by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosus.

Authors:  Kenneth G Coggins; Ann Latour; Mytrang S Nguyen; Laurent Audoly; Thomas M Coffman; Beverly H Koller
Journal:  Nat Med       Date:  2002-02       Impact factor: 53.440

2.  [Familial idiopathic hypertrophic osteoarthropathy and atopic dermatitis (Currarino's disease)].

Authors:  P Pillet; F Boralévi; J F Chateil; E Pinlou; D Lacombe
Journal:  Arch Pediatr       Date:  2002-09       Impact factor: 1.180

3.  Familial idiopathic osteoarthropathy.

Authors:  G CURRARINO; R C TIERNEY; R G GIESEL; C WEIHL
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1961-04

Review 4.  Pachydermoperiostosis: an update.

Authors:  M Castori; L Sinibaldi; R Mingarelli; R S Lachman; D L Rimoin; B Dallapiccola
Journal:  Clin Genet       Date:  2005-12       Impact factor: 4.438

5.  easyLINKAGE-Plus--automated linkage analyses using large-scale SNP data.

Authors:  K Hoffmann; T H Lindner
Journal:  Bioinformatics       Date:  2005-07-12       Impact factor: 6.937

6.  Mutation in the HPGD gene encoding NAD+ dependent 15-hydroxyprostaglandin dehydrogenase underlies isolated congenital nail clubbing (ICNC).

Authors:  M Tariq; Z Azeem; G Ali; M S Chishti; W Ahmad
Journal:  J Med Genet       Date:  2008-09-19       Impact factor: 6.318

7.  Critical residues for the coenzyme specificity of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase.

Authors:  Hoon Cho; Marcos A Oliveira; Hsin-Hsiung Tai
Journal:  Arch Biochem Biophys       Date:  2003-11-15       Impact factor: 4.013

8.  Mutations in the gene encoding the lamin B receptor produce an altered nuclear morphology in granulocytes (Pelger-Huët anomaly).

Authors:  Katrin Hoffmann; Christine K Dreger; Ada L Olins; Donald E Olins; Leonard D Shultz; Barbara Lucke; Hartmut Karl; Reinhard Kaps; Dietmar Müller; Amparo Vayá; Justo Aznar; Russell E Ware; Norberto Sotelo Cruz; Tom H Lindner; Harald Herrmann; André Reis; Karl Sperling
Journal:  Nat Genet       Date:  2002-07-15       Impact factor: 38.330

9.  Cranio-osteoarthropathy in sibs.

Authors:  Tabib Dabir; A M Sills; Christine M Hall; Chris Bennett; Louise C Wilson; Raoul C M Hennekam
Journal:  Clin Dysmorphol       Date:  2007-07       Impact factor: 0.816

10.  Congenital cardiac disease as a core feature of cranio-osteoarthropathy.

Authors:  Susan O'Connell; Mohnish Suri; Desmond Duff; Jeremiah Kelleher; Christine M Hall; William Reardon
Journal:  Clin Dysmorphol       Date:  2004-10       Impact factor: 0.816

View more
  5 in total

1.  Exome sequencing identifies SLCO2A1 mutations as a cause of primary hypertrophic osteoarthropathy.

Authors:  Zhenlin Zhang; Weibo Xia; Jinwei He; Zeng Zhang; Yaohua Ke; Hua Yue; Chun Wang; Hao Zhang; Jiemei Gu; Weiwei Hu; Wenzhen Fu; Yunqiu Hu; Miao Li; Yujuan Liu
Journal:  Am J Hum Genet       Date:  2011-12-22       Impact factor: 11.025

2.  Primary hypertrophic osteoarthropathy caused by homozygous deletion in HPGD gene in a family: changing clinical and radiological findings with long-term follow-up.

Authors:  Beyhan Tüysüz; Saliha Yılmaz; Özgür Kasapçopur; Tuğba Erener-Ercan; Emre Ceyhun; Kaya Bilguvar; Murat Günel
Journal:  Rheumatol Int       Date:  2014-05-12       Impact factor: 2.631

3.  The first case of primary hypertrophic osteoarthropathy with soft tissue giant tumors caused by HPGD loss-of-function mutation.

Authors:  Qianqian Pang; Yuping Xu; Xuan Qi; Yan Jiang; Ou Wang; Mei Li; Xiaoping Xing; Ling Qin; Weibo Xia
Journal:  Endocr Connect       Date:  2019-06       Impact factor: 3.335

4.  Clinical and biochemical characteristics of 12 Chinese primary hypertrophic osteoarthropathy patients with HPGD mutations.

Authors:  Qi Lu; Yang Xu; Shanshan Li; Zeng Zhang; Jiagen Sheng; Zhenlin Zhang
Journal:  Int J Biol Sci       Date:  2022-06-06       Impact factor: 10.750

5.  Novel SLCO2A1 mutations cause gender differentiated pachydermoperiostosis.

Authors:  Lijuan Yuan; Xihui Chen; Ziyu Liu; Dan Wu; Jianguo Lu; Guoqiang Bao; Sijia Zhang; lIfeng Wang; Yuanming Wu
Journal:  Endocr Connect       Date:  2018-08-01       Impact factor: 3.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.